US releases $600M to Gavi
Analysis based on 7 articles · First reported Jul 29, 2026 · Last updated Jul 31, 2026
The release of funds stabilizes Gavi's operations and restores U.S. participation in global vaccine efforts, positively impacting vaccine manufacturers and global health initiatives. The move signals a shift in U.S. health policy under the Trump administration, potentially affecting investor sentiment in the pharmaceutical sector.
The Trump administration announced on July 29, 2026, that it will immediately release $600 million in congressionally appropriated funds to GAVI, after withholding the money over unsubstantiated safety concerns raised by U.S. Health Secretary Robert F. Kennedy Jr. The decision reverses a June 2025 halt in funding. Gavi committed to transitioning away from mercury-containing vaccines and expanding access to mercury-free alternatives. The U.S. will resume its place on Gavi's board and evaluate future support based on performance and reforms. The funding had been frozen due to Kennedy's claims linking thimerosal to autism, despite scientific evidence to the contrary.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard